Javascript must be enabled to continue!
Creation of a Multi-Year Pediatric Candidemia Antibiogram in Georgia Identifies Changing Epidemiology and Resistance Trends
View through CrossRef
Background: Invasive candidiasis, including candidemia, is a significant cause of morbidity and mortality in medically complex and immunocompromised children. Understanding the epidemiology and antifungal susceptibility patterns of Candida infections could help guide empiric antifungal therapy. Methods: This fungal antibiogram was created at a large quaternary children’s health system in Georgia. Blood isolates positive for Candida spp. from 2019 through 2023 were included. The number and percentage of isolates for each Candida spp was recorded by year and then as the combined 5-year total. The Clinical and Laboratory Standards Institute (CLSI) antifungal interpretative criteria were used, and we only included one unique Candida spp isolate per patient. Due to the limited number of isolates, the combined 5 years of isolates were used to create the fungal antibiogram. Data are shown as percent susceptible using CLSI interpretative criteria and number of isolates. Results: Between 2019 and 2023 there were 124 unique blood isolates of Candida spp identified. The most common isolates were C. albicans (33%), C. parapsilosis (27%), C. glabrata (14%) and C. tropicalis (11%). Over the 5 years of the study, the percentage of C. albicans isolates decreased from 47% to 21%. The change in epidemiology was not driven by a single Candida species but varied from year to year. For C. albicans, susceptibility was 100% for fluconazole and micafungin. For C. parapsilosis, susceptibility to fluconazole and micafungin was 97% and 94%, respectively. Fluconazole susceptibility was lowest for C. glabrata (88%) and C. krusei (0%). Using CLSI epidemiological cutoff values (ECV) to evaluate the amphotericin B results, none of the isolates had results greater than the CLSI ECVs. Comparing 2019 and 2023, the percentage of Candida blood isolates resistant to fluconazole increased from 5% to 18.5%. Conclusion: C. albicans was the most frequently identified cause of candidemia in children, but there was a gradual increase in fungemia caused by other Candida spp. over the past 5 years including Candida with fluconazole resistance. Overall, our findings demonstrate high susceptibility rates to fluconazole and echinocandins in Candida spp. blood isolates. Further research is needed to identify risk factors for antifungal resistant candidemia in pediatric patients.Disclosure: Mark Gonzalez: Honoria for a one time consulation with NaviDx consulting in May of 2022. Honoria from the American Society for Microbiology for writing of a chapter in the Clinical Microbiology Procedures Handbook.
Cambridge University Press (CUP)
Title: Creation of a Multi-Year Pediatric Candidemia Antibiogram in Georgia Identifies Changing Epidemiology and Resistance Trends
Description:
Background: Invasive candidiasis, including candidemia, is a significant cause of morbidity and mortality in medically complex and immunocompromised children.
Understanding the epidemiology and antifungal susceptibility patterns of Candida infections could help guide empiric antifungal therapy.
Methods: This fungal antibiogram was created at a large quaternary children’s health system in Georgia.
Blood isolates positive for Candida spp.
from 2019 through 2023 were included.
The number and percentage of isolates for each Candida spp was recorded by year and then as the combined 5-year total.
The Clinical and Laboratory Standards Institute (CLSI) antifungal interpretative criteria were used, and we only included one unique Candida spp isolate per patient.
Due to the limited number of isolates, the combined 5 years of isolates were used to create the fungal antibiogram.
Data are shown as percent susceptible using CLSI interpretative criteria and number of isolates.
Results: Between 2019 and 2023 there were 124 unique blood isolates of Candida spp identified.
The most common isolates were C.
albicans (33%), C.
parapsilosis (27%), C.
glabrata (14%) and C.
tropicalis (11%).
Over the 5 years of the study, the percentage of C.
albicans isolates decreased from 47% to 21%.
The change in epidemiology was not driven by a single Candida species but varied from year to year.
For C.
albicans, susceptibility was 100% for fluconazole and micafungin.
For C.
parapsilosis, susceptibility to fluconazole and micafungin was 97% and 94%, respectively.
Fluconazole susceptibility was lowest for C.
glabrata (88%) and C.
krusei (0%).
Using CLSI epidemiological cutoff values (ECV) to evaluate the amphotericin B results, none of the isolates had results greater than the CLSI ECVs.
Comparing 2019 and 2023, the percentage of Candida blood isolates resistant to fluconazole increased from 5% to 18.
5%.
Conclusion: C.
albicans was the most frequently identified cause of candidemia in children, but there was a gradual increase in fungemia caused by other Candida spp.
over the past 5 years including Candida with fluconazole resistance.
Overall, our findings demonstrate high susceptibility rates to fluconazole and echinocandins in Candida spp.
blood isolates.
Further research is needed to identify risk factors for antifungal resistant candidemia in pediatric patients.
Disclosure: Mark Gonzalez: Honoria for a one time consulation with NaviDx consulting in May of 2022.
Honoria from the American Society for Microbiology for writing of a chapter in the Clinical Microbiology Procedures Handbook.
Related Results
P193 Candidemia in coronavirus disease 2019 patients in a university hospital in Buenos Aires, Argentina
P193 Candidemia in coronavirus disease 2019 patients in a university hospital in Buenos Aires, Argentina
Abstract
Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM
It is known that the incidence and epidemiology of candidemia ...
Incidence and risk factors for COVID‐19 associated candidemia (CAC) in ICU patients
Incidence and risk factors for COVID‐19 associated candidemia (CAC) in ICU patients
AbstractBackgroundCritically ill COVID‐19 patients have a high risk for the development of candidemia due to being exposed to both well‐defined classical risk factors and COVID‐19‐...
P-1727. Defining Uncomplicated Candidemia suitable for “shorter is better” Treatment
P-1727. Defining Uncomplicated Candidemia suitable for “shorter is better” Treatment
Abstract
Background
The success of candidemia treatment depends on patient baseline characteristics, as well as clinical ...
Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes
Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes
A retrospective study of 76 episodes of candidemia in 73 patients with underlying hematological malignancy, from 1988 until 1997, has been conducted to evaluate the clinical charac...
P150 Profile of Candidemia in a national level HAI Surveillance Network of India
P150 Profile of Candidemia in a national level HAI Surveillance Network of India
Abstract
Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM
Background...
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
BACKGROUND:
A workforce analysis was conducted to predict whether the projected future supply of pediatric anesthesiologists is balanced with the requirements o...
Development and validation of COVID‐19 associated candidemia score (CAC‐Score) in ICU patients
Development and validation of COVID‐19 associated candidemia score (CAC‐Score) in ICU patients
AbstractBackgroundThe development of candidemia is a highly fatal condition in severe COVID‐19 infection.ObjectivesThis study aimed to develop a candidemia prediction score in COVI...
Mapping Microbial Resistance: Unveiling Regional Patterns through Atlanta’s Antibiogram Development
Mapping Microbial Resistance: Unveiling Regional Patterns through Atlanta’s Antibiogram Development
Background:
Multidrug resistance remains one of the top global health threats and has been rising over recent decades, jeopardizing patient outcomes and increas...

